Stockscreener 앱 받기
16.52
1.37%
-0.23
시간 외 거래:
16.67
0.15
+0.91%
전일 마감가:
$16.75
열려 있는:
$16.8
하루 거래량:
4.19M
Relative Volume:
1.31
시가총액:
$3.94B
수익:
$426.45M
순이익/손실:
$197.67M
주가수익비율:
20.15
EPS:
0.82
순현금흐름:
$110.10M
1주 성능:
-14.54%
1개월 성능:
-7.24%
6개월 성능:
-1.14%
1년 성능:
+35.52%
1일 변동 폭
$16.45
$17.48
1주일 범위
$14.62
$20.26
52주 변동 폭
$14.62
$25.67
Adma Biologics Inc Stock (ADMA) Company Profile
명칭
Adma Biologics Inc
전화
(201) 478-5552
주소
C/O ADMA BIOLOGICS, INC., RAMSEY
ADMA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ADMA
Adma Biologics Inc
|
16.52 | 4.43B | 426.45M | 197.67M | 110.10M | 0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-07-19 | 재개 | Raymond James | Strong Buy |
| 2022-10-13 | 개시 | Mizuho | Buy |
| 2021-11-11 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2021-11-09 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-06-04 | 개시 | Jefferies | Buy |
| 2019-04-15 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-07 | 재개 | H.C. Wainwright | Buy |
| 2017-12-11 | 재확인 | Maxim Group | Buy |
| 2017-11-14 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2017-01-23 | 업그레이드 | Maxim Group | Hold → Buy |
| 2016-08-01 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2016-07-25 | 재확인 | Maxim Group | Buy |
| 2015-05-13 | 재확인 | Maxim Group | Buy |
| 2014-12-08 | 개시 | Oppenheimer | Outperform |
| 2014-12-01 | 재확인 | Maxim Group | Buy |
모두보기
Adma Biologics Inc 주식(ADMA)의 최신 뉴스
ADMA projects $1.1B revenue before 2030 as yield enhancement drives margin expansion and ASCENIV growth - MSN
ADMA Biologics: Optionality With SG-001 And A Vertically Integrated IG Platform - Seeking Alpha
ADMA Beats on Q2 Earnings and Revenues, Asceniv Drives Momentum - MSN
ADMA Biologics Thrives With Blockbuster Growth And New FDA Edge - Finimize
ADMA Biologics: A Better Quarter Than Headline Numbers (NASDAQ:ADMA) - Seeking Alpha
ADMA Biologics, Inc. (NASDAQ:ADMA) Q2 2025 Earnings Call Transcript - Insider Monkey
ADMA Biologics 2025 Q2 Earnings Strong Performance as Net Income Rises 6.7% - AInvest
ADMA Biologics Secures $300M Credit Agreement with JPMorgan - AInvest
ADMA Biologics Earnings Call Highlights Robust Growth - TipRanks
Noteworthy Thursday Option Activity: ADMA, SMMT, ICHR - Nasdaq
ADMA Biologics Sees Promising Gains Amid Strategic Shifts and Rising Market Trends - timothysykes.com
Plasma Derived Medicine Market to Reach USD 37.4 Billion by 2034, Growing at 8.05% CAGR - GlobeNewswire Inc.
ADMA Beats On Q2 Earnings And Revenues, Asceniv Drives Momentum - Barchart.com
Redwire Posts Downbeat Q2 Results, Joins Tandem Diabetes Care, Fortinet, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Earnings call transcript: ADMA Biologics Q2 2025 misses earnings expectations By Investing.com - Investing.com South Africa
Adma Biologics (ADMA) Q2 Revenue Up 14% - AOL.com
ADMA Biologics Reports Strong Q2 2025 Results - TipRanks
ADMA Biologics Q2 2025 Earnings Call Transcript - MarketBeat
ADMA Biologics Outpaces Expectations With Upbeat Growth Plans - Finimize
ADMA Biologics Rides ASCENIV Demand To Higher Guidance - Finimize
ADMA Biologics (ADMA) Projects Significant Growth with Yield Pro - GuruFocus
ADMA Biologics: A Tale of Two Narratives—Strong Fundamentals vs. a Pessimistic Rating - AInvest
ADMA Biologics' Q2 2025: Unraveling Contradictions in Yield Enhancements, Reimbursement, and Demand Dynamics - AInvest
ADMA Biologics Q2 2025 Earnings Call Transcript Review - AInvest
ADMA Biologics' Q2 2025 Earnings and Strategic Outlook: Navigating Insider Sales and Risk Disclosures for Long-Term Value - AInvest
ADMA Biologics Inc earnings missed, revenue fell short of estimates By Investing.com - Investing.com Canada
ADMA Biologics Inc earnings missed, revenue fell short of estimates - Investing.com
Transcript : ADMA Biologics, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Adma Biologics (ADMA) Q2 Earnings and Revenues Beat Estimates - Yahoo Finance
Adma Biologics: Q2 Earnings Snapshot - San Antonio Express-News
Adma Biologics Q2 Earnings: Impressive Growth in Net Income and RevenueNews and Statistics - IndexBox
ADMA BIOLOGICS, INC. SEC 10-Q Report - TradingView
Why ADMA Biologics Shares Are Under Pressure - TipRanks
ADMA Biologics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Adma Biologics reports Q2 EPS 14c, consensus 14c - TipRanks
ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update - The Manila Times
ADMA Biologics Reports 14% YoY Revenue Growth and Significant Financial Milestones in 2Q 2025 - Quiver Quantitative
Is ADMA Biologics Inc. a growth stock or a value stockDouble-digit growth - Jammu Links News
How strong is ADMA Biologics Inc. company’s balance sheetMaximize gains with data-driven trading alerts - Jammu Links News
What are analysts’ price targets for ADMA Biologics Inc. in the next 12 monthsFind the best stocks for sustainable growth - Jammu Links News
Is ADMA Biologics Inc. a good long term investmentAccelerated financial growth - Jammu Links News
Is ADMA Biologics Inc. stock overvalued or undervaluedOutstanding yields - Jammu Links News
Is it the right time to buy ADMA Biologics Inc. stockBuild a diversified portfolio for steady growth - Jammu Links News
What institutional investors are buying ADMA Biologics Inc. stockMaximize gains with timely market signals - Jammu Links News
What analysts say about ADMA Biologics Inc. stockInvest in high-yield stocks with confidence - Jammu Links News
What catalysts could drive ADMA Biologics Inc. stock higher in 2025Find the best stocks for sustainable growth - Jammu Links News
ADMA Biologics Inc. warns investors of significant business risks in latest report. - AInvest
What drives ADMA Biologics Inc. stock priceUnlock your trading potential with expert tips - Jammu Links News
ADMA Biologics Inc. Warns Investors of Significant Business Risks in Latest Report - The Globe and Mail
Is ADMA Biologics Inc. Forming a Consolidation BaseWatchlist for Smart Swing Trading Updated - metal.it
ADMA Biologics Inc. May Be Forming Higher Low — Chartwatchers AlertSmart Trade Plans With Risk Protection Explained - metal.it
Adma Biologics Inc (ADMA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):